The National Pharmaceutical Pricing Authority (NPPA), under the Department of Pharmaceuticals, has fixed the ceiling prices ...

Hims & Hers delivered strong Q2 growth, driven by compounded GLP-1 offerings, but faces uncertainty as regulatory and supply ...

Novo Nordisk remains a strong buy despite share price dip, thanks to its robust drug pipeline, massive market potential, and ...

Pfizer (PFE) increased its 2025 profit outlook by 10 cents a share to a range of $2.90 a share to $3.10 a share, citing continued cost cuts, a lower tax rate and "confidence" that strength seen in the ...

President Donald Trump has given major pharmaceutical companies 60 days to slash prescription drug prices or face action.

As prescription drug prices continue to rise, many patients are left wondering how their costs are determined.

Average selling prices of Illuccix will likely decrease when its transitional pass-through payment status expires in 2025.

Trump gives drugmakers 60 days to match U.S. prescription prices with lower international rates, aiming to cut costs for ...

Pfizer Inc. reports its Q2 earnings soon, carrying the weight of a 10% stock dip this year. The company, known for its ...

Days after he sent letters instructing top pharmaceutical manufacturers to use a “most favored nation” pricing model for ...

Swiss generic drug manufacturer Sandoz plans to launch unbranded weight-loss drugs in Canada at discounts of up to 70% compared to branded versions once patents begin to expire next year, CEO Richard ...